ANZ Updates Regarding APRA’s Action Against IOOF

On 7 December 2018, the Australian Prudential Regulation Authority (APRA) announced a number of actions against IOOF entities (ASX: IFL), directors and executives as they fail to act in the best interests of superannuation members.

APRA has started the disqualification proceedings and is planning to impose additional license conditions. APRA is also going to issue directions to APRA-regulated entities in the IOOF group. Further APRA has also started the proceedings in Australia’s Federal Court for the disqualification of 5 individuals that were responsible for IIML and Questor Financial Services Limited.

IOOF’s Managing Director (MD) Mr. Chris Kelaher, Chairperson Mr. George Venardos, CFO Mr. David Coulter, General Manager Mr. Paul Vine and General Counsel Mr. Gary Riordan are the individuals who are included in the disqualification proceedings.

As per APRA’s Deputy Chair Helen Rowell, APRA has been trying to resolve its concerns with IOOF for many years, however, IOOF was not making adequate progress, which is why APRA decided to take stronger action. If APRA gets through with its disqualification proceedings it would prohibit the above individuals from being or acting as a responsible person of a trustee of a superannuation entity.

Through the proceedings, APRA is also seeking a court declaration that IIML and Questor breached the SIS Act and APRA also considers that IIML, Questor and the relevant individuals did not appropriately acknowledge and address issues concerning conflicts of interest raised by APRA from 2015 to date.

APRA has identified three separate occasions in 2015, in which Questor and IIML contravened the SIS Act by differentially compensating the superannuation beneficiaries and other non-superannuation investors for losses caused by Questor, IIML or their service providers. This means that the superannuation beneficiaries were compensated from their own reserve funds rather than the trustees’ own funds or third-party compensation.

Sponsored ad by Kalkine

Following the APRA’s announcement, Australia and New Zealand Banking Group Limited (ASX: ANZ) provided an update on the sale of its Wealth businesses. Earlier in the month of October 2017, ANZ announced regarding the sale of its OnePath Pensions and Investments business to IOOF.

With regards to the APRA’ action, ANZ’s Deputy CEO Mr. Alexis George said the bank is planning to seek the urgent information from both IOOF and APRA and it is going to assess the various options available.

He added further that the work to separate Pensions and Investments from ANZ’s Life Insurance business will continue and there is a framework available to complete the Zurich transaction that does not involve IOOF. The share price of ANZ is up 0.429 percent on 7 December 2018.

In the last six months, the share price of ANZ decreased by 3.21% as on 6 December 2018 and traded at a PE ratio of 11.810x. ANZ’s shares traded at $25.780 with a market capitalization of circa $73.62 billion as on 7 December 2018 (AEST 12:30 PM).  On the other hand, IFL was down -34.868%.


This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report


Please enter your comment!
Please enter your name here